Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Literature DB >> 25845879

Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Sofia Costa-de-Oliveira¹, Isabel M Miranda², Ana Silva-Dias², Ana P Silva², Acácio G Rodrigues³, Cidália Pina-Vaz⁴.

Abstract

Candida albicans is the most prevalent cause of fungemia worldwide. Its ability to develop resistance in patients receiving azole antifungal therapy is well documented. In a murine model of systemic infection, we show that ibuprofen potentiates fluconazole antifungal activity against a fluconazole-resistant strain, drastically reducing the fungal burden and morbidity. The therapeutic combination of fluconazole with ibuprofen may constitute a new approach for the management of antifungal therapeutics to reverse the resistance conferred by efflux pump overexpression.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 25845879 PMCID： PMC4468673 DOI： 10.1128/AAC.05056-14

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

25 in total

Review 1. Candida albicans dimorphism as a therapeutic target.

Authors: Ilse D Jacobsen; Duncan Wilson; Betty Wächtler; Sascha Brunke; Julian R Naglik; Bernhard Hube
Journal: Expert Rev Anti Infect Ther Date: 2012-01 Impact factor: 5.091

Review 2. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors: M A Pfaller; D J Diekema
Journal: J Clin Microbiol Date: 2012-06-27 Impact factor: 5.948

3. Organ-specific innate immune responses in a mouse model of invasive candidiasis.

Authors: Michail S Lionakis; Jean K Lim; Chyi-Chia Richard Lee; Philip M Murphy
Journal: J Innate Immun Date: 2010-11-09 Impact factor: 7.349

4. In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp.

Authors: Tarcieli P Venturini; Luana Rossato; Tatiana B Spader; Giordano R Tronco-Alves; Maria Izabel Azevedo; Caroline B Weiler; Janio M Santurio; Sydney Hartz Alves
Journal: Diagn Microbiol Infect Dis Date: 2011-08-15 Impact factor: 2.803

Review 5. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.

Authors: Michael A Pfaller
Journal: Am J Med Date: 2012-01 Impact factor: 4.965

6. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

Authors: J Liu; J D Farmer; W S Lane; J Friedman; I Weissman; S L Schreiber
Journal: Cell Date: 1991-08-23 Impact factor: 41.582

Review 7. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.

Authors: M E Cardenas; M C Cruz; M Del Poeta; N Chung; J R Perfect; J Heitman
Journal: Clin Microbiol Rev Date: 1999-10 Impact factor: 26.132

8. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.

Authors: R J Arceci; K Stieglitz; B E Bierer
Journal: Blood Date: 1992-09-15 Impact factor: 22.113

9. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.

Authors: M C Arendrup; E Dzajic; R H Jensen; H K Johansen; P Kjaeldgaard; J D Knudsen; L Kristensen; C Leitz; L E Lemming; L Nielsen; B Olesen; F S Rosenvinge; B L Røder; H C Schønheyder
Journal: Clin Microbiol Infect Date: 2013-04-22 Impact factor: 8.067

10. Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis.

Authors: Brian M Peters; Glen E Palmer; Andrea K Nash; Elizabeth A Lilly; Paul L Fidel; Mairi C Noverr
Journal: Infect Immun Date: 2013-11-11 Impact factor: 3.441

10 in total

1. [Candiduria! What now? : Therapy of urinary tract infections with Candida].

Authors: H Hof
Journal: Urologe A Date: 2017-02 Impact factor: 0.639

Review 2. Drug resistance and tolerance in fungi.

Authors: Judith Berman; Damian J Krysan
Journal: Nat Rev Microbiol Date: 2020-02-11 Impact factor: 60.633

3. Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models.

Authors: K M T Astvad; D Sanglard; E Delarze; R K Hare; M C Arendrup
Journal: Antimicrob Agents Chemother Date: 2018-11-26 Impact factor: 5.191

4. In Vitro Interactions between Non-Steroidal Anti-Inflammatory Drugs and Antifungal Agents against Planktonic and Biofilm Forms of Trichosporon asahii.

Authors: Suteng Yang; Yong Liao; Lin Cong; Xuelian Lu; Rongya Yang
Journal: PLoS One Date: 2016-06-08 Impact factor: 3.240

Review 5. Potential Antifungal Targets against a Candida Biofilm Based on an Enzyme in the Arachidonic Acid Cascade-A Review.

Authors: Xinning Liu; Decai Wang; Cuixiang Yu; Tao Li; Jianqiao Liu; Shujuan Sun
Journal: Front Microbiol Date: 2016-12-06 Impact factor: 5.640

Review 10. Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.

Authors: Sofia Costa-de-Oliveira; Acácio G Rodrigues
Journal: Microorganisms Date: 2020-01-22